emerg
recent
year
new
microbiolog
techniqu
consider
improv
possibl
obtain
higher
diagnost
yield
commun
acquir
pneumonia
cap
discoveri
antimicrobi
agent
offer
new
treatment
option
made
necessari
revis
modif
spanish
societi
pulmonolog
thorac
surgeri
separ
guidelin
diagnosi
treatment
cap
purpos
bring
line
current
scientif
evid
guidelin
deal
exclus
cap
immunocompet
adult
patient
year
older
address
manag
diseas
children
patient
cancer
immunodepress
patient
gener
patient
discharg
hospit
within
preced
day
institution
patient
opinion
type
patient
patient
upper
respiratori
tract
infect
involv
lung
requir
differ
treatment
therefor
fall
outsid
scope
guidelin
recommend
organ
section
epidemiolog
diagnosi
predict
rule
treatment
literatur
review
one
topic
initi
draft
drawn
basi
draft
discuss
edit
meet
attend
member
panel
consensu
reach
final
joint
document
recommend
consensu
document
grade
class
accord
level
evid
level
welldesign
prospect
trial
random
appropri
methodolog
level
ii
welldesign
prospect
studi
control
without
random
level
iii
retrospect
studi
case
expert
opinion
final
approv
consensu
document
review
critic
panel
review
attend
earlier
meet
order
facilit
easi
comprehens
quick
read
recommend
text
supplement
numer
tabl
summari
locat
end
text
summari
tabl
highlight
opinion
import
aspect
diagnosi
treatment
prevent
cap
although
difficult
estim
incid
accur
cap
common
diseas
europ
incid
rang
case
per
popul
per
year
two
populationbas
studi
patient
age
spain
found
annual
incid
rate
rang
episod
per
popul
predomin
episod
older
men
winter
level
ii
evid
percentag
cap
patient
hospit
variabl
rang
variabl
caus
varieti
factor
includ
differ
admiss
criteria
possibl
receiv
treatment
hospit
emerg
depart
percentag
patient
come
nurs
retir
home
avail
hospit
bed
one
spanish
studi
report
patient
hospit
cap
admit
intens
care
unit
icu
metaanalysi
studi
compris
patient
reveal
overal
mortal
rang
ambulatori
patient
patient
treat
icu
etiolog
etiolog
diagnosi
made
cap
case
depend
number
techniqu
employ
case
mild
pneumonia
condit
gener
manag
outsid
hospit
rare
separ
work
group
communityacquir
pneumonia
tuberculosi
respiratori
infect
tir
assembl
necessari
establish
etiolog
distribut
pathogen
respons
cap
clinic
set
discuss
outpati
cap
group
tabl
show
frequenc
common
pathogen
ambulatori
hospit
patient
europ
total
studi
spanish
analyz
nine
dealt
specif
outpati
cap
level
ii
evid
spanish
studi
carri
use
mainli
serolog
diagnost
method
found
would
expect
predomin
atyp
microorgan
recent
studi
correl
etiolog
case
pneumonia
class
fine
predict
rule
pathogen
found
class
patient
atyp
mycoplasma
pneumonia
common
level
ii
evid
class
ii
iii
case
howev
typic
pathogen
account
streptococcu
pneumonia
common
basi
data
current
avail
therefor
common
caus
pathogen
case
cap
treat
outsid
hospit
pneumonia
pneumonia
etiolog
establish
patient
hospit
cap
level
ii
evid
pneumonia
predomin
pathogen
new
techniqu
use
establish
etiolog
found
least
third
cap
case
diagnos
convent
method
pneumococc
origin
preval
atyp
pathogen
exclud
legionella
organ
depend
effort
invest
identifi
case
seri
cite
atyp
pathogen
mainli
pneumonia
identifi
caus
agent
case
cap
case
caus
haemophilu
influenza
gramneg
bacilli
staphylococcu
aureu
less
common
aspir
pneumonia
account
cap
case
case
infect
legionella
speci
occur
sporad
year
round
epidem
occur
frequent
summer
month
incid
legionella
speci
highest
mediterranean
area
import
outbreak
observ
part
spain
de
henar
recent
spanish
studi
viru
detect
patient
cap
sole
pathogen
half
case
level
ii
evid
pathogen
may
isol
type
pneumonia
common
mix
etiolog
combin
typic
atyp
pathogen
although
signific
find
unclear
etiolog
defin
mix
reliabl
method
reveal
concurr
presenc
pathogen
gener
result
found
spanish
literatur
similar
european
find
shown
tabl
european
studi
publish
last
decad
particularli
spain
tabl
pneumonia
legionella
organ
respons
case
sever
cap
level
ii
evid
gramneg
bacilli
third
common
pathogen
case
seri
possibl
tuberculosi
also
consid
spain
especi
hemoptysi
microorgan
isol
final
consider
given
possibl
diseas
may
caus
opportunist
pathogen
pneumocysti
jiroveci
associ
human
immunodefici
viru
hiv
infect
aspergillu
speci
patient
chronic
obstruct
pulmonari
diseas
copd
receiv
corticosteroid
therapi
sever
patient
ill
condit
type
pathogen
expect
yield
diagnost
method
use
percentag
unidentifi
pathogen
significantli
lower
intub
compar
nonintub
patient
vs
moreov
significantli
higher
incid
among
intub
patient
pseudomona
aeruginosa
vs
legionella
pneumophila
vs
level
iii
evid
prospect
multicent
studi
spain
cap
patient
age
etiolog
identifi
patient
level
ii
evid
pathogen
often
isol
follow
pneumonia
h
influenza
l
pneumophila
anoth
spanish
studi
adult
cap
pneumonia
isol
patient
year
old
l
pneumophila
caus
pathogen
subset
elderli
patient
significantli
lower
percentag
found
cohort
younger
patient
level
ii
evid
although
etiolog
pneumonia
acquir
spanish
retir
nurs
home
analyz
caus
pathogen
isol
set
unit
state
america
differ
found
case
pneumonia
contract
home
notabl
exampl
residenti
care
set
high
frequenc
aureu
level
ii
evid
howev
find
confirm
studi
carri
control
group
unit
kingdom
level
ii
evid
main
pathogen
isol
spanish
multicent
studi
patient
copd
hospit
cap
pneumonia
chlamydophila
pneumonia
h
influenza
level
ii
patient
sever
copd
especi
presenc
bronchiectasi
p
aeruginosa
also
consid
level
ii
evid
congest
heart
failur
risk
factor
cap
viral
infect
diabet
mellitu
favor
bacterem
pneumococc
pneumonia
cap
caus
aureu
level
ii
evid
alcohol
independ
risk
factor
cap
sever
present
difficult
associ
particular
cap
etiolog
alcohol
comorbid
common
aspir
pneumonia
common
alcohol
patient
level
ii
evid
bronchopulmonari
aspir
oropharyng
content
associ
condit
circumst
depress
patient
level
consciousnessstrok
degen
diseas
head
injuri
drug
intox
gener
anesthesiaand
circumst
alter
anatomi
laryngopharyng
region
intub
presenc
tumor
etiolog
usual
polymicrobi
predomin
anaerob
microorgan
level
ii
evid
bacteri
pneumonia
particular
diseas
caus
pneumonia
common
infect
hivposit
patient
patient
acquir
immunodefici
syndrom
although
mention
pathogen
less
commonli
found
cap
also
frequent
seen
seroposit
patient
level
ii
evid
smoke
associ
increas
risk
cap
irrespect
etiolog
smoker
time
like
nonsmok
contract
invas
pneumococc
diseas
level
ii
evid
associ
smoke
cap
caus
c
pneumonia
legionella
infect
also
mark
level
ii
evid
risk
respiratori
infect
patient
receiv
longterm
corticosteroid
therapi
relat
dose
use
patient
underli
diseas
accumul
mg
prednison
dose
mgday
increas
patient
risk
infect
one
spanish
studi
identifi
aspergillu
speci
aureu
pathogen
often
isol
patient
take
corticosteroid
level
ii
evid
certain
case
factor
relat
host
hobbi
travel
occup
exposur
may
point
specif
etiolog
inform
help
orient
decis
diagnost
method
use
select
appropri
empir
treatment
tabl
level
iii
evid
increas
incid
cap
caus
legionella
infect
report
spain
particularli
mediterranean
area
although
case
isol
outbreak
affect
larg
number
peopl
occur
particularli
summer
month
common
sourc
infect
aerosol
gener
cool
tower
hotwat
instal
level
evid
coxiella
burnetii
although
tradit
consid
c
burnetii
common
northern
part
spain
bacteria
also
play
import
role
etiolog
cap
region
level
ii
evid
chlamydophila
psittaci
psittacosi
zoonosi
caus
inhal
organ
wast
product
fece
urin
feather
respiratori
secret
contain
c
psittaci
although
diseas
tradit
associ
exot
farm
bird
psittacosi
also
transmit
anim
mean
incid
area
agricultur
activ
probabl
somewhat
higher
usual
believ
countri
epidem
describ
among
farm
worker
veterinarian
outbreak
report
spain
occur
within
famili
affect
small
number
patient
taken
varieti
clinic
form
syndrom
diagnosi
cap
base
presenc
sign
symptom
acut
infect
conjunct
recent
appear
radiograph
pulmonari
infiltr
unexplain
process
level
iii
evid
view
variabl
clinic
present
cap
physician
convers
epidemiolog
geograph
area
work
also
use
particularli
healthi
young
adult
patient
differenti
typic
atyp
clinic
present
typic
clinic
present
character
abrupt
onset
less
hour
chill
fever
excess
product
cough
purul
sputum
pleurit
chest
pain
notabl
featur
atyp
clinic
pictur
unproduct
cough
vagu
chest
discomfort
nonpulmonari
sign
symptom
joint
pain
headach
alter
conscious
gastrointestin
disord
vomit
diarrhea
find
sometim
associ
cap
leukocytosi
leukopenia
respiratori
sound
consist
diagnosi
pulmonari
consolid
sensit
less
found
isol
new
radiograph
infiltr
two
featur
born
mind
discrep
clinic
radiograph
cours
diseas
characterist
atyp
pneumonia
frequent
presenc
hyponatremia
hypophosphatemia
hematuria
pneumonia
caus
legionella
speci
mental
confus
worsen
underli
diseas
uncommon
older
patient
even
fever
complet
blood
count
routin
biochemistri
well
puls
oximetri
arteri
blood
gase
particularli
recommend
patient
underli
heart
lung
diseas
perform
pneumonia
patient
come
hospit
test
serv
assess
sever
diseas
possibl
need
hospit
level
iii
evid
sinc
clinic
sign
symptom
cap
specif
chest
radiograph
must
obtain
follow
reason
confirm
diagnosi
provid
inform
locat
extent
diseas
explor
possibl
complic
pleural
effus
cavit
detect
underli
pulmonari
diseas
altern
diagnos
monitor
progress
resolut
diseas
limit
imag
techniqu
discrimin
pneumonia
noninfecti
inflammatori
infiltr
detect
small
infiltr
seen
sensit
method
comput
tomographi
routin
posteroanterior
later
chest
radiograph
univers
recommend
patient
suspect
pneumonia
level
ii
evid
singl
radiograph
pattern
identifi
etiolog
pneumonia
even
differenti
group
pathogen
level
ii
evid
classic
pattern
lobar
pneumonia
bronchial
pneumonia
interstiti
pneumonia
exclus
associ
etiolog
agent
although
identif
pattern
use
case
level
iii
evid
bilater
involv
involv
lobe
exist
pleural
effus
indic
sever
level
iii
evid
particularli
bilater
pleural
effus
whether
caus
pneumonia
associ
heart
failur
level
ii
evid
sinc
radiograph
cure
almost
alway
lag
behind
clinic
cure
may
sometim
take
week
longer
systemat
radiographi
discharg
hospit
necessari
radiograph
confirm
cure
still
essenti
tabl
imposs
establish
firm
etiolog
diagnosi
basi
clinic
radiograph
find
level
ii
evid
even
appropri
diagnost
techniqu
use
hospit
set
etiolog
diagnosi
establish
case
prospect
studi
undertaken
identifi
test
use
determin
etiolog
cap
patient
furthermor
absenc
proof
identif
respons
pathogen
influenc
prognosi
given
rise
differ
opinion
need
establish
etiolog
howev
suggest
earli
etiolog
diagnosi
correl
rapid
improv
start
treatment
inappropri
antibiot
therapi
associ
poor
prognosi
consequ
seriou
cap
diagnost
techniqu
use
none
techniqu
necessari
mild
case
level
iii
evid
howev
start
antimicrobi
treatment
never
delay
order
obtain
reliabl
sampl
diagnost
techniqu
also
use
patient
respond
empir
treatment
case
slowli
resolv
cap
level
iii
evid
bacteria
isol
respiratori
sampl
may
repres
colon
unless
inevit
pathogen
organ
l
pneumophila
mycobacterium
tuberculosi
therefor
order
obtain
firm
etiolog
diagnosi
often
necessari
isol
microorgan
detect
antigen
specif
fragment
genom
uncontamin
sampl
blood
urin
pleural
fluid
lung
tissu
els
detect
signific
quantiti
specif
antibodi
serum
probabl
diagnosi
reach
use
quantifi
respiratori
isol
certain
condit
level
ii
evid
microbiolog
techniqu
potenti
use
etiolog
diagnosi
cap
classifi
noninvas
invas
clear
consensu
concern
microbiolog
techniqu
use
process
sputum
sampl
cap
gram
stain
aerob
cultur
cultur
buffer
charcoalyeast
extract
legionella
organ
difficult
obtain
adequ
sampl
highli
contamin
oral
secret
fewer
squamou
cell
polymorphonuclear
cell
per
power
field
murray
level
iv
v
prospect
case
seri
hospit
cap
patient
sputum
sampl
fulfil
criteria
author
report
differ
fine
risk
class
yield
sputum
gram
stain
aerob
cultur
carri
recent
collect
reliabl
sputum
sampl
patient
hospit
cap
level
ii
evid
sputum
sampl
transport
process
rapidli
possibl
minut
antibiot
treatment
start
particularli
presenc
resist
atyp
microorgan
suspect
level
ii
evid
gram
stain
find
may
guid
therapi
level
iii
evid
cultur
result
correl
gram
stain
use
determin
possibl
resist
pathogen
antimicrobi
agent
sputum
cultur
medium
suitabl
legionella
organ
recommend
epidem
outbreak
even
urin
sampl
test
posit
legionella
antigen
cultur
facilit
diagnosi
infect
serogroup
legionella
speci
l
pneumophila
use
identifi
link
clinic
environment
strain
way
molecular
marker
induc
sputum
sampl
valu
detect
tuberculosi
p
jiroveci
patient
unabl
expector
use
epidemiolog
context
immun
statu
patient
make
test
advis
level
evid
direct
immunofluoresc
assay
respiratori
secret
may
also
use
diagnos
cap
caus
legionella
speci
although
sensit
test
patient
adequ
expector
sinc
test
use
serotypespecif
antibodi
diagnost
yield
depend
speci
legionella
serotyp
use
practic
perform
blood
cultur
ambulatori
manag
cap
unjustifi
owe
low
diagnost
yield
costeffect
patient
hospit
cap
remain
question
time
prudent
recommend
particularli
seriou
case
serial
blood
cultur
perform
patient
admit
cap
posit
result
test
etiolog
prognost
valu
level
ii
evid
attempt
ration
use
blood
cultur
cap
recent
studi
propos
decis
whether
blood
cultur
obtain
could
base
patient
risk
develop
bacteremia
urinari
antigen
test
rapid
immunochromatograph
techniqu
controversi
concentr
urin
use
test
appear
moder
loss
sensit
associ
use
direct
urin
compens
simplif
rapid
techniqu
specif
remain
close
spain
consid
reason
determin
urinari
pneumococc
antigen
unconcentr
urin
case
cap
requir
hospit
level
ii
evid
fals
posit
report
patient
nonpneumococc
infect
caus
streptococcu
organ
case
posit
persist
week
resolut
cap
sinc
result
pneumococc
urinari
antigen
test
complement
sputum
gram
stain
patient
capabl
expector
adequ
use
techniqu
recommend
immunochromatograph
urinari
antigen
assay
becom
gold
standard
method
diagnos
legionnair
diseas
case
proper
concentr
thermal
treatment
urin
essenti
adequ
sensit
obtain
despit
hour
process
time
involv
level
ii
evid
ultracentrifug
urin
probabl
valid
altern
done
much
quickli
without
loss
either
sensit
specif
level
ii
evid
urin
test
legionella
antigen
follow
case
hospit
patient
enigmat
pneumonia
sputum
gram
stain
pneumococc
urinari
antigen
assay
patient
fulfil
criteria
sever
pneumonia
patient
whose
condit
fail
respond
treatment
betalactam
antibiot
case
coincid
suspect
epidem
outbreak
legionnair
diseas
commun
yield
aerob
anaerob
cultur
gram
stain
pleural
fluid
low
nevertheless
thoracocentesi
recommend
pleural
effus
associ
cap
undetect
empyema
one
factor
predict
treatment
failur
within
hour
hospit
admiss
case
test
pleural
fluid
sampl
antigen
may
yield
addit
diagnos
obtain
routin
method
level
iii
evid
pneumococc
antigen
success
detect
pleural
fluid
use
immunochromatograph
membran
assay
binax
use
test
yet
standard
serolog
test
usual
use
differenti
diagnosi
pneumonia
caus
intracellular
agent
view
limit
clinic
util
routin
use
techniqu
recommend
level
iii
evid
outsid
except
circumst
suspect
outbreak
legionnair
diseas
tularem
pneumonia
commun
epidemiolog
studi
sensit
specif
immunoglobulinm
detect
suffici
high
recommend
routin
use
techniqu
even
respect
classic
serolog
studi
base
measur
immunoglobul
reason
doubt
rais
concern
specif
test
certain
agent
c
pneumonia
legionella
speci
polymeras
chain
reaction
techniqu
identifi
pathogen
caus
cap
way
fragment
dna
obtain
biolog
sampl
sputum
blood
pleural
fluid
urin
fall
outsid
routin
clinic
practic
spanish
hospit
assess
predict
valu
posit
neg
problemat
routin
use
techniqu
therefor
recommend
better
understand
techniqu
howev
sought
hospit
technic
infrastructur
resourc
carri
use
invas
techniqu
indic
sever
case
cap
involv
patient
whose
condit
deterior
rapidli
fail
respond
initi
empir
antibiot
treatment
tabl
although
studi
suggest
etiolog
diagnosi
improv
prognosi
patient
sever
cap
invas
diagnost
techniqu
includ
transtrach
aspir
transthorac
fine
needl
aspir
techniqu
involv
fiberopt
bronchoscopi
telescop
cathet
protect
specimen
brush
bronchoalveolar
lavag
bal
procedur
must
carri
expert
personnel
level
iii
evid
transtrach
aspir
longer
use
uncontamin
specimen
lung
parenchyma
obtain
transthorac
fine
needl
aspir
techniqu
highli
specif
wherea
sensit
vari
greatli
case
seri
even
procedur
perform
expert
sensit
improv
significantli
cultur
sampl
complement
antigen
detect
gene
amplif
techniqu
level
ii
evid
although
polymeras
chain
reaction
sensit
techniqu
latex
agglutin
latter
often
use
costeffect
quicker
simpler
provid
use
inform
support
decis
concern
initi
treatment
level
ii
evid
transthorac
fine
needl
aspir
may
consid
case
abscess
cap
patient
respond
treatment
seriou
complic
associ
techniqu
pneumothorax
hemoptysi
open
lung
biopsi
invas
techniqu
use
except
rare
provid
relev
inform
immunocompet
patient
cap
numer
studi
shown
bronchoscop
techniqu
provid
use
microbiolog
inform
ventilatorassoci
pneumonia
also
cap
highest
sensit
obtain
quantit
cultur
bal
best
specif
quantit
cultur
protect
specimen
brush
cutoff
point
use
differenti
colon
infect
protect
specimen
brush
coloni
form
unit
per
millilit
sensit
protect
brush
method
vari
specif
quit
high
paramet
influenc
prior
antibiot
therapi
perform
test
hour
initi
antibiot
therapi
may
neg
influenc
number
microorgan
isol
percentag
posit
result
obtain
techniqu
level
ii
evid
bal
cutoff
point
diagnosi
bacteri
pneumonia
coloni
form
unit
per
millilit
result
obtain
techniqu
correl
highli
diagnosi
base
protect
brush
cathet
specimen
histolog
examin
lung
presenc
intracellular
microorgan
predict
posit
result
quantit
cultur
specif
marker
bacteri
infect
consequ
use
techniqu
recommend
whenev
bal
perform
bal
appear
diagnost
techniqu
choic
case
slowli
evolv
cap
facilit
diagnosi
unsuspect
infect
greater
degre
probabl
techniqu
case
cap
respond
empir
antibiot
treatment
sampl
obtain
use
protect
specimen
brush
bal
modifi
treatment
obfusc
presenc
unusu
resist
persist
pathogen
sever
cap
initi
assess
basi
prognost
factor
decid
appropri
care
settingoutpati
treatment
hospit
icuand
identifi
appropri
empir
antibiot
treatment
seri
risk
factor
associ
increas
morbid
mortal
identifi
use
classic
metaanalysi
factor
group
follow
patientdepend
factor
age
comorbid
b
factor
relat
cap
episod
clinic
analyt
radiograph
find
sinc
singl
prognost
factor
capabl
predict
death
suffici
sensit
specif
multivari
analysi
use
analysi
make
possibl
identifi
independ
risk
factor
predict
valu
past
decad
variou
author
devis
predict
rule
estim
risk
death
patient
cap
rule
develop
deal
object
fundament
manag
patient
cap
identifi
patient
low
risk
death
may
suitabl
outpati
treatment
b
recogn
patient
high
risk
death
must
hospit
use
model
base
multivari
statist
analysi
fine
et
al
develop
predict
rule
stratifi
patient
class
respect
risk
death
fine
risk
class
pneumonia
sever
index
rule
deriv
data
patient
cap
includ
seri
studi
unit
state
america
independ
valid
differ
cohort
patient
pneumonia
patient
outcom
research
team
studi
fine
rule
predict
mortal
assign
point
case
base
variabl
patient
stratifi
class
basi
result
score
tabl
class
iii
patient
low
risk
death
class
iv
risk
death
class
v
high
risk
death
identifi
patient
risk
death
class
iiii
rule
becom
tool
use
decid
outpati
treatment
appropri
patient
fall
class
ii
receiv
outpati
treatment
patient
class
iii
requir
brief
inpati
observ
patient
classifi
class
iv
v
hospit
appli
differ
popul
rule
shown
predict
risk
death
accur
particularli
patient
year
old
although
abil
predict
hospit
weaker
one
foremost
limit
fine
rule
score
base
variabl
obtain
use
analyt
techniqu
sole
avail
hospit
anoth
disadvantag
may
underestim
sever
diseas
young
patient
moreov
rule
take
account
social
factor
patient
person
circumst
may
import
decid
whether
hospit
necessari
prospect
studi
undertaken
verifi
use
fine
rule
admiss
decis
shown
use
reduc
proport
admiss
low
risk
class
increas
proport
readmiss
week
reason
hospit
patient
fall
low
risk
class
numer
one
observ
studi
conclud
fine
pneumonia
sever
index
low
posit
predict
valu
indic
inappropri
hospit
adequ
detect
sever
comorbid
diseas
patient
social
circumst
case
nonsever
cap
patient
lower
risk
class
admiss
justifi
requir
hospit
owe
social
factor
owe
inabl
take
oral
medic
prior
treatment
failur
owe
suspect
sepsi
spain
respiratori
insuffici
pleural
complic
report
common
motiv
hospit
admiss
longer
hospit
stay
patient
cap
fall
lower
fine
risk
class
valid
fine
predict
rule
propos
made
includ
addit
factor
order
improv
predict
valu
respect
hospit
admiss
fact
report
patient
admit
icu
cap
lowrisk
pneumonia
sever
index
iiii
british
thorac
societi
develop
predict
rule
call
base
variabl
patient
age
subsequ
simplifi
name
acronym
variabl
confus
urea
mmoll
respiratori
rate
blood
pressur
diastol
mm
hg
systol
age
year
deriv
cohort
studi
patient
accur
stratifi
patient
respect
risk
death
british
thorac
societi
guidelin
recommend
patient
level
confus
evalu
use
test
compris
question
simpli
evalu
outward
sign
disorient
person
place
time
final
score
rang
risk
death
associ
score
deriv
cohort
follow
hospit
recommend
patient
score
higher
especi
presenc
indic
sever
hypoxemia
multilobar
pneumonia
studi
valid
simplifi
rule
exclud
urea
valu
use
primari
care
set
call
score
rang
risk
death
associ
score
follow
sinc
basi
inform
current
avail
predict
rule
deliv
conclus
predict
valu
establish
risk
death
physician
clinic
judgment
must
take
preced
hospit
decis
decis
taken
casebycas
basi
gener
fine
pneumonia
sever
index
consid
use
detect
patient
low
risk
death
rule
detect
patient
high
risk
recent
guidelin
issu
infecti
diseas
societi
america
defin
process
decid
initi
site
treatment
patient
cap
first
step
assess
preexist
condit
might
compromis
safeti
home
care
includ
respiratori
insuffici
social
psychiatr
problem
substanc
abus
inabl
take
oral
medic
second
step
condit
rule
calcul
fine
risk
class
third
step
involv
clinic
judgment
order
individu
applic
fine
risk
class
casebycas
basi
today
new
option
emerg
care
patient
cap
also
evalu
includ
home
hospit
day
hospit
admiss
observ
unit
studi
undertaken
specif
evalu
option
adopt
standard
criteria
referr
patient
cap
icu
difficult
depend
variou
factor
consider
variat
hospit
percentag
patient
cap
admit
icu
highlight
difficulti
standard
criteria
clinic
assess
sever
difficult
tendenc
underestim
sever
clear
definit
sever
cap
exist
criteria
use
mechan
ventil
homogen
reflect
sever
patient
condit
rather
variabl
hospit
separ
initi
guidelin
consid
admiss
icu
presenc
follow
complic
sever
respiratori
insuffici
hemodynam
instabl
renal
failur
requir
dialysi
dissemin
intravascular
coagul
mening
coma
level
iii
evid
earlier
guidelin
american
british
thorac
societi
fine
pneumonia
sever
index
propos
variou
criteria
admiss
icu
abil
discrimin
low
order
improv
criteria
one
studi
propos
use
rule
base
factor
classifi
major
criteria
need
mechan
ventil
presenc
septic
shock
minor
criteria
systol
pressur
mm
hg
multilobar
involv
ratio
pao
fraction
inspir
oxygen
presenc
major
minor
criteria
would
indic
referr
icu
modif
increas
specif
maintain
sensit
predict
valu
formula
still
rel
low
improv
result
obtain
earlier
american
british
guidelin
pneumonia
sever
index
british
sever
score
also
use
decid
admiss
icu
score
greater
valid
case
sever
cap
defin
presenc
clinic
featur
reflect
acronym
sensit
specif
predict
death
need
intens
care
impact
comorbid
diseas
case
cap
treat
icu
poorli
understood
report
presenc
neoplast
neurolog
cardiac
diseas
may
caus
death
patient
sever
cap
copd
signific
impact
mortal
sever
cap
associ
home
oxygen
therapi
howev
factor
extent
lung
injuri
nonpulmonari
organ
system
failur
immunosuppress
advanc
age
signific
impact
case
sever
cap
avail
intermedi
care
unit
use
noninvas
mechan
ventil
may
influenc
decis
initi
site
care
repres
econom
therapeut
option
associ
lower
level
nosocomi
infect
antimicrobi
treatment
patient
cap
prescrib
empir
evalu
sever
case
like
etiolog
preval
resist
strain
among
microorgan
commonli
found
area
take
factor
account
clinician
choos
appropri
empir
treatment
target
microorgan
probabl
involv
level
ii
iii
evid
accord
recent
studi
strain
pneumonia
spain
reduc
resist
penicillin
highlevel
resist
decreas
presenc
follow
factor
indic
increas
risk
pneumococci
reduc
sensit
betalactam
antibiot
age
year
chronic
lung
diseas
alcohol
immunodefici
multipl
comorbid
contact
children
hospit
treatment
betalactam
antibiot
preced
month
preval
macrolid
resist
spain
two
type
macrolid
resist
describ
highlevel
resist
minimum
inhibitori
dose
erythromycin
higher
caus
alter
ribosom
rna
affect
macrolid
insensit
dose
increas
lowlevel
resist
minimum
inhibitori
dose
mediat
increas
activ
cytoplasm
efflux
pump
confin
macrolid
lowlevel
macrolid
resist
less
common
spain
overcom
dose
increas
numer
factor
indic
possibl
pneumococc
resist
fluoroquinolon
describ
presenc
copd
nosocomi
infect
resid
nurs
retir
home
prior
treatment
fluoroquinolon
empir
monotherapi
fluoroquinolon
avoid
immunodefici
patient
treat
antibiot
preced
month
given
lack
random
trial
larg
number
patient
cap
treat
differ
antibiot
avail
scant
evid
base
recommend
concern
antimicrobi
treatment
case
antibiot
therapi
must
start
earli
hour
cap
diagnos
strategi
reduc
mortal
length
stay
hospit
level
ii
evid
addit
patient
clinic
condit
must
reassess
within
hour
initi
antibiot
treatment
group
patient
mild
cap
therefor
treat
outpati
clinic
pictur
group
patient
sever
main
focu
antimicrobi
treatment
treat
pneumococcu
given
increas
preval
strain
pneumonia
reduc
sensit
penicillin
macrolid
need
mani
case
cover
atyp
pathogen
young
patient
certain
epidem
situat
case
clinic
sign
symptom
highli
suggest
recommend
treatment
patient
group
telithromycin
mgday
els
one
new
fluoroquinolon
levofloxacin
mgday
moxifloxacin
mgday
taken
oral
anoth
possibl
option
high
dose
oral
amoxicillin
least
g
everi
hour
regimen
effect
pneumococc
strain
reduc
sensit
betalactam
antibioticsplu
macrolid
oral
azithromycin
mg
daili
oral
clarithromycin
mg
everi
hour
view
high
incid
macrolideresist
pneumococci
spain
predomin
mechan
resist
monotherapi
macrolid
prescrib
subset
group
patient
suitabl
outpati
manag
despit
concurr
chronic
diseas
risk
factor
atyp
etiolog
h
influenza
enterobacteria
case
first
line
treatment
singledrug
therapi
oral
fluoroquinolon
provid
effect
pneumococc
cover
levofloxacin
moxifloxacin
amoxicillinclavulan
acid
could
use
altern
treatment
alway
bear
mind
lack
activ
atyp
microorgan
group
patient
hospit
clinic
reason
group
pneumonia
still
common
caus
pathogen
high
probabl
patient
factor
associ
increas
risk
antibioticresist
pneumococci
enter
gramneg
bacilli
prior
cardiopulmonari
diseas
associ
diseas
antibiot
therapi
preced
month
atyp
pathogen
includ
legionella
organ
may
involv
approxim
pneumonia
etiolog
establish
circumst
therefor
initi
empir
treatment
includ
follow
regimen
thirdgener
cephalosporin
cefotaxim
h
ceftriaxon
h
administ
intraven
amoxicillinclavulan
acid
h
combin
macrolid
administ
intraven
combin
macrolid
amoxicillin
clavulan
acid
h
use
treat
mani
patient
urinari
antigen
test
l
pneumophila
neg
macrolid
may
omit
patient
treat
betalactam
antibiot
alon
howev
suggest
combin
betalactam
macrolid
effect
monotherapi
betalactam
alon
reduc
mortal
patient
cap
especi
bacteremia
controversi
hypothesi
random
studi
necessari
clarifi
situat
level
ii
evid
anoth
equal
valid
treatment
option
could
use
antipneumococc
fluoroquinolon
levofloxacin
moxifloxacin
level
ii
evid
fact
regimen
report
associ
lower
risk
treatment
failur
justifi
use
case
kind
patient
present
sever
cap
requir
admiss
icu
group
select
homogen
group
treat
high
dose
thirdgener
cephalosporin
cefotaxim
h
ceftriaxon
h
administ
intraven
alway
combin
macrolid
clarithromycin
h
azithromycin
mgday
administ
intraven
antipneumococc
fluoroquinolon
intraven
levofloxacin
mgday
case
risk
factor
infect
p
aeruginosa
broadspectrum
antibiot
therapi
day
preced
month
presenc
bronchiectasi
malnutrit
diseas
treatment
associ
neutrophil
dysfunct
patient
must
treat
combin
therapi
includ
effect
coverag
p
aeruginosa
legionella
speci
potenti
resist
pneumonia
achiev
fourthgener
cephalosporin
cefepim
h
piperacillintazobactam
h
imipenem
meropenem
h
combin
fluoroquinolon
ciprofloxacin
h
levofloxacin
h
administ
intraven
author
suggest
carbapenemfluoroquinolon
combin
avoid
potenti
risk
acquir
crossresist
combin
betalactam
aminoglycosid
prefer
tobramycin
amikacin
anoth
altern
regimen
synergist
effect
antibiot
compens
poor
pulmonari
penetr
aminoglycosid
infect
anaerob
microorgan
suspect
necrosi
cavit
chest
radiographi
suspect
aspir
amoxicillinclavulan
acid
administ
high
dose
amoxicillin
g
altern
clindamycin
plu
thirdgener
cephalosporin
els
singledrug
therapi
ertapenem
moxifloxacin
admiss
icu
necessari
cephalosporin
replac
combin
piperacillin
tazobactam
tabl
show
recommend
dose
treatment
regimen
earli
switch
initi
parenter
treatment
oral
treatment
switch
therapi
antimicrobi
treatment
patient
cap
play
import
role
reduc
mean
length
stay
hospit
cost
treatment
without
compromis
patient
safeti
switch
therapi
indic
minimum
durat
empir
parenter
antimicrobi
therapi
day
time
requir
stabil
patient
condit
case
criteria
use
switch
therapi
abil
take
oral
medic
absenc
fever
improv
resolut
sign
symptom
pneumonia
hemodynam
stabil
absenc
mental
confus
unstabl
comorbid
septic
metastasi
activ
infect
level
ii
evid
patient
may
discharg
hospit
hour
clinic
stabl
optimum
durat
antibiot
treatment
difficult
establish
case
cap
usual
treat
day
although
shorter
regimen
day
tri
new
antibiot
longer
mean
halflif
attempt
achiev
similar
clinic
bacteriolog
result
lower
drug
consumpt
would
favor
improv
patient
adher
facilit
reduct
resist
level
iii
evid
given
lack
studi
recommend
shorter
treatment
durat
antibiot
therapi
day
hospit
patient
day
ambulatori
patient
gener
durat
treatment
also
condit
sever
patient
condit
presenc
underli
diseas
bacteremia
cours
diseas
caus
pathogen
never
less
day
case
cap
caus
l
pneumophila
aureu
p
aeruginosa
may
extend
week
patient
pulmonari
cavit
suspect
infect
anaerob
microorgan
level
ii
evid
gener
measur
undertaken
patient
cap
includ
rest
abund
liquid
maintain
correct
hydrat
level
antipyret
medic
reduc
fever
analges
chest
pain
support
measur
may
necessari
patient
sever
cap
includ
oxygen
therapi
maintain
arteri
oxygen
satur
pao
mm
hg
mechan
ventil
event
acut
respiratori
insuffici
replac
liquid
andor
pressor
amin
maintain
proper
blood
pressur
sever
case
cap
noninvas
mechan
ventil
shown
improv
respiratori
insuffici
reduc
rate
orotrach
intub
length
stay
icu
although
therapeut
benefit
occur
subgroup
patient
copd
level
evid
studi
found
although
noninvas
mechan
ventil
initi
improv
oxygen
sever
cap
subsequ
intub
requir
patient
level
iii
evid
view
larg
number
complic
poor
prognosi
associ
orotrach
intub
patient
copd
sever
cap
noninvas
mechan
ventil
tri
initi
patient
sever
cap
develop
hypoxem
respiratori
insuffici
noninvas
mechan
ventil
associ
signific
reduct
need
endotrach
intub
mortal
day
compar
initi
oxygen
therapi
deliv
high
inspir
fraction
oxygen
initi
therapeut
test
noninvas
mechan
ventil
strict
monitor
failur
indic
therefor
recommend
high
risk
patient
care
assess
admiss
use
predict
rule
reevalu
frequent
ensur
earli
detect
deterior
clinic
oximetr
paramet
need
increas
fraction
inspir
oxygen
alter
patient
mental
state
respiratori
metabol
acidosi
indic
need
intens
care
patient
patient
cap
respond
treatment
group
includ
case
improv
gener
clinic
pictur
delay
occur
well
patient
whose
condit
continu
deterior
despit
antimicrobi
treatment
caus
lack
respons
divers
tabl
case
must
reevalu
patient
respond
treatment
includ
thorough
revis
medic
histori
new
bacteriolog
studi
perform
use
noninvas
even
invas
techniqu
via
flexibl
bronchoscop
complement
techniqu
chest
comput
tomographi
may
play
key
role
determin
chang
made
antibiot
treatment
level
iii
evid
cap
prevent
combat
pathogen
caus
diseas
prototyp
strategi
specif
vaccin
pneumonia
tri
elimin
risk
factor
favor
occurr
way
influenza
vaccin
antismok
campaign
two
kind
pneumococc
vaccin
current
use
polysaccharid
vaccin
contain
purifi
capsular
polysaccharid
antigen
serotyp
caus
pneumococc
infect
children
adult
effect
prevent
invas
pneumococc
infect
bacteremia
mening
infect
steril
site
caus
serotyp
b
heptaval
conjug
vaccin
protect
serotyp
caus
case
otiti
media
pneumonia
mening
children
polysaccharid
vaccin
administ
patient
acut
pneumococc
infect
neither
recommend
pregnanc
breastfeed
less
effect
patient
defici
immun
system
although
scientif
associ
recommend
use
case
even
advis
revaccin
year
peopl
administ
second
dose
vaccin
receiv
primari
vaccin
previou
year
year
old
time
although
second
dose
within
year
primari
vaccin
formal
contraind
possibl
sever
reaction
could
occur
high
circul
level
antibodi
level
iii
evid
revaccin
recommend
circumst
except
case
patient
age
asplenia
antipneumococc
vaccin
administ
concurr
vaccin
influenza
vaccin
differ
site
use
level
evid
spain
influenza
epidem
occur
winter
month
affect
popul
peopl
vaccin
influenza
shown
effect
prevent
attenu
viral
diseas
older
younger
peopl
efficaci
depend
similar
circul
viru
sequenc
vaccin
administ
prevent
diseas
healthi
peopl
although
efficaci
lower
older
peopl
patient
chronic
debilit
diseas
vaccin
still
attenu
diseas
caus
influenza
viru
patient
reduc
incid
lower
respiratori
tract
infect
complic
mortal
associ
influenza
infect
popul
high
risk
complic
age
year
adult
children
pulmonari
cardiovascular
diseas
includ
asthma
resid
close
institut
adult
children
monitor
hospit
previou
year
chronic
metabol
diseas
includ
diabet
mellitu
renal
failur
hemoglobinopathi
defici
immun
statu
includ
immunodefici
caus
drug
hiv
children
adolesc
year
treat
extend
period
acetylsalicyl
acid
order
prevent
develop
rey
syndrom
pregnant
women
second
third
trimest
influenza
season
children
month
popul
risk
transmit
influenza
peopl
high
risk
healthcar
personnel
contact
patient
peopl
work
geriatr
nurs
home
peopl
take
care
patient
chronic
diseas
peopl
work
residenti
facil
shelter
peopl
high
risk
worker
provid
home
help
peopl
high
risk
individu
includ
children
live
peopl
high
risk
peopl
live
children
age
month
peopl
provid
special
servic
commun
direct
contact
popul
shop
assist
cashier
public
establish
tour
guid
student
kind
influenza
vaccin
inactiv
vaccin
contain
dead
virus
administ
intramuscular
inject
use
person
month
old
includ
healthi
popul
peopl
suffer
chronic
diseas
attenu
vaccin
contain
live
virus
capabl
reproduct
administ
intranas
expens
approv
healthi
popul
age
year
includ
peopl
direct
contact
highrisk
popul
attenu
vaccin
administ
peopl
histori
syndrom
children
adolesc
receiv
long
term
treatment
acetylsalicyl
acid
pregnant
women
peopl
allerg
egg
protein
concern
possibl
advers
event
limit
use
influenza
vaccin
patient
although
inactiv
vaccin
contain
live
virus
therefor
caus
influenza
infect
local
reaction
slight
usual
last
hour
howev
fever
malais
myalgia
may
occur
hour
vaccin
rare
occas
immedi
allerg
reaction
occur
patient
hypersensit
egg
fear
advers
event
syndrom
associ
vaccin
given
smoke
princip
risk
factor
invas
diseas
caus
pneumonia
young
peopl
furthermor
increas
risk
cap
incid
sever
pneumonia
caus
chickenpox
legionella
organ
risk
develop
cap
decreas
year
smoker
give
habit
level
evid
incid
spain
cap
adult
episod
per
popul
per
year
predomin
winter
month
tend
common
older
male
level
ii
evid
percentag
patient
cap
hospit
variabl
approxim
cap
patient
admit
icu
overal
mortal
attribut
cap
estim
around
vari
patient
admit
icu
treat
outpati
etiolog
cap
episod
establish
case
common
caus
agent
patient
manag
outsid
hospit
group
pneumonia
follow
pneumonia
tabl
pneumonia
also
common
pathogen
patient
hospit
cap
group
although
pneumonia
h
influenza
gramneg
bacilli
legionella
speci
also
common
group
tabl
patient
cap
admit
icu
group
caus
microorgan
pneumonia
legionella
speci
gramneg
bacilli
also
common
pathogen
group
level
ii
evid
tabl
pneumonia
common
caus
agent
cap
peopl
spain
follow
consider
distanc
h
influenza
l
pneumophila
level
ii
evid
case
cap
affect
patient
copd
pathogen
often
isol
pneumonia
c
pneumonia
h
influenza
level
ii
evid
p
aeruginosa
also
consid
level
ii
evid
patient
sever
copd
comorbid
bronchiectasi
smoker
time
like
suffer
invas
pneumococc
diseas
nonsmok
syndrom
diagnosi
cap
base
presenc
sign
symptom
acut
infect
associ
recent
pulmonari
radiograph
infiltr
unexplain
process
level
iii
evid
complet
blood
count
routin
biochemistri
puls
oximetri
arteri
blood
ga
analysi
perform
patient
pneumonia
come
hospit
order
assess
sever
evalu
need
hospit
level
iii
evid
posteroanterior
later
chest
radiograph
obtain
hospit
patient
cap
ambulatori
patient
clinic
improv
observ
hour
empir
treatment
level
iii
evid
bilater
multilobar
lobe
radiograph
involv
pleural
effus
indic
sever
diseas
level
iii
evid
radiograph
cure
often
lag
behind
clinic
cure
may
sometim
take
week
longer
necessari
obtain
chest
radiograph
discharg
patient
hospit
essenti
obtain
radiograph
confirm
cure
etiolog
diagnosi
tabl
gener
sever
case
cap
techniqu
use
obtain
etiolog
diagnosi
test
necessari
case
mild
cap
level
iii
evid
start
antimicrobi
therapi
never
delay
order
obtain
reliabl
sampl
etiolog
diagnosi
gram
stain
cultur
recent
sputum
minut
old
recommend
patient
hospit
cap
especi
presenc
resist
atyp
microorgan
suspect
level
ii
evid
sever
case
cap
serial
blood
cultur
perform
posit
result
test
etiolog
prognost
valu
level
ii
evid
consid
reason
test
pneumococc
urinari
antigen
case
cap
requir
hospit
level
ii
evid
urin
test
legionella
organ
follow
case
hospit
patient
enigmat
cap
sputum
gram
stain
andor
pneumococc
urinari
antigen
assay
patient
fulfil
sever
criteria
respond
betalactam
antibiot
therapi
case
coincid
suspect
epidem
outbreak
legionnair
diseas
commun
serolog
test
polymeras
chain
reaction
specimen
obtain
use
noninvas
method
recommend
routin
clinic
practic
level
iii
evid
use
invas
techniqu
obtain
etiolog
diagnosi
cap
indic
patient
whose
condit
deterior
rapidli
fail
respond
initi
empir
antibiot
treatment
fine
rule
use
detect
patient
cap
low
risk
death
recommend
siteofcar
decis
outpati
hospit
care
rule
presenc
condit
indic
sever
could
repres
obstacl
home
treatment
includ
instabl
associ
diseas
hemodynam
instabl
respiratori
insuffici
pleural
effus
inabl
take
oral
medic
evalu
social
circumst
social
problem
substanc
abus
psychiatr
problem
might
compromis
adher
treatment
level
ii
evid
calcul
predict
score
patient
classifi
fine
group
ii
may
sent
home
hospit
observ
consid
patient
classifi
fine
group
iii
patient
classifi
fine
group
iv
v
admit
hospit
nonhospit
clinic
set
rule
use
determin
need
hospitalizationa
score
level
ii
evid
criteria
admiss
icu
septic
shock
need
mechan
ventil
level
iii
evid
presenc
follow
criteria
systol
blood
pressur
mm
hg
ratio
pao
fraction
inspir
oxygen
level
ii
evid
score
scale
level
ii
evid
initi
antibiot
therapi
patient
cap
establish
empir
assess
sever
like
etiolog
preval
common
microorgan
geograph
area
incid
spain
pneumonia
decreas
sensit
penicillin
highlevel
resist
decreas
macrolid
resist
rang
predominantli
highlevel
resist
affect
macrolid
unrespons
dose
increas
antibiot
treatment
start
earli
possibl
within
hour
cap
diagnosi
strategi
shown
reduc
mortal
length
stay
hospit
level
ii
evid
patient
clinic
condit
reevalu
hour
start
antibiot
therapi
patient
cap
manag
outsid
hospit
fundament
aim
antibiot
treatment
treat
pneumonia
tabl
outpati
group
includ
subgroup
patient
chronic
comorbid
diseas
risk
factor
atyp
pathogen
patient
requir
specif
treatment
tabl
patient
hospit
cap
pneumonia
must
treat
common
pathogen
physician
also
bear
mind
higher
risk
among
hospit
patient
cap
caus
resist
pneumococci
gramneg
enter
bacilli
atyp
pathogen
includ
legionella
speci
tabl
patient
cap
requir
admiss
icu
treat
high
dose
thirdgener
cephalosporin
plu
macrolid
antipneumococc
fluoroquinolon
tabl
cap
patient
risk
factor
infect
p
aeruginosa
treat
combin
therapi
effect
pathogen
also
provid
coverag
resist
pneumococci
legionella
speci
switch
therapi
play
import
role
effort
reduc
mean
length
stay
hospit
overal
cost
treatment
without
compromis
patient
safeti
minimum
durat
empir
parenter
antimicrobi
treatment
day
patient
may
discharg
hospit
hour
clinic
stabl
optimum
total
durat
antibiot
treatment
difficult
establish
gener
maintain
day
patient
cap
manag
outsid
hospit
day
hospit
patient
patient
cap
caus
l
pneumophila
aureu
p
aeruginosa
treat
least
day
present
pulmonari
cavit
suspect
infect
anaerob
microorgan
may
requir
treatment
sever
week
level
ii
evid
gener
measur
manag
cap
includ
correct
hydrat
analges
antipyret
support
measur
oxygen
therapi
mechan
ventil
case
sever
respiratori
insuffici
replac
fluid
andor
pressor
amin
maintain
adequ
blood
pressur
case
sever
respiratori
failur
patient
copd
sever
cap
noninvas
mechan
ventil
tri
initi
level
evid
respiratori
failur
occur
patient
sever
cap
copd
noninvas
mechan
ventil
start
evolut
patient
condit
monitor
close
level
evid
caus
nonrespond
cap
numer
tabl
vaccin
influenza
shown
effect
prevent
attenu
viral
diseas
older
younger
peopl
antipneumococc
vaccin
effect
prevent
invas
pneumococc
diseas
bacteremia
mening
infect
steril
site
heptaval
pneumococc
conjug
vaccin
protect
patient
serotyp
caus
case
otiti
media
pneumonia
mening
children
stop
smoke
reduc
risk
cap
year
quit
level
evid
